Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN Symposium 2018 /
WINTHER & SPRING: Targeted agents and triple agent combinations

25th - 26th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.18
Views: 1246

Dr Razelle Kurzrock - UC San Diego Moores Cancer Center, San Diego, USA

Dr Kurzrock speaks with ecancer at the 2018 WIN symposium about the WINTHER and SPRING trials from the WIN consortium.

She highlights the importance of comparing the RNA levels between the tumour and the normal tissue as these can greatly vary, a unique aspect of the WINTHER trial.

Dr Kurzrock also describes some of the statistics involved and why this was so integral to WINTHER.

Lastly Dr Kurzrock outlines the progress of the SPRING trial which began just a few months ago, and has it's first few patients being treated.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation